Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis

Open label, prospective, non-interventional, single arm study in patients receiving KOVALTRY
as prophylaxis therapy.

Inclusion Criteria:

- Male patients diagnosed with moderate to severe hemophilia A (≤ 5% FVIII:C (Factor
VIII Coagulant activity))

- Any age

- ≥ 50 exposure days (EDs) to any FVIII product

- Patients with or without history of inhibitors

- Patient with previous history of inhibitors, with at least 2 consecutive negative
inhibitor tests and on standard prophylaxis therapy for at least 1 year prior to
study entry

- No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor

- Evidence of FVIII inhibitor as measured by the Nijmegen-modified Bethesda
assay[<0.6 Bethesda units (BU/mL)] or Bethesda assay [< 1.0 BU/mL] in 2 on
consecutives samples

- Documented or clinical suspicion of shortened FVIII half-life (< 6 hrs)

- Currently on or plan to start prophylaxis therapy with KOVALTRY

- Written informed consent

Exclusion Criteria:

- Patients participating in an investigational program with interventions outside of
routine clinical practice

- Patients with an additional diagnosis of any bleeding/coagulation disorder other than
hemophilia A

- Patients on Immune Tolerance Induction (ITI) treatment at the time of enrollment